Orchid Pharma Limited share price
NSE: ORCHPHARMA · ISIN INE191A01027
Key numbers
- Market cap
- ₹ 5,401 Cr
- Current price
- ₹ 1,064.90
- 52-week high / low
- ₹ 1,144 / 480
- Stock P/E
- 323.7
- Book value
- ₹ 254.0
- Dividend yield
- 0.00%
- ROCE
- 1.1%
- ROE
- 0.6%
- Debt to equity
- 0.20
- Sales growth (3 yrs)
- 22.3%
- Profit growth (3 yrs)
- -40.1%
- 1-year return
- 44.2%
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including beta-lactam. It serves pharma companies, generic drug manufacturers, healthcare distributors, and institutional and government buyers. The company also exports its products to approximately 40 countries internationally. It has a strategic collaboration with Cipla for marketing across India. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 263 | 194 | 207 | 238 | 304 |
| Operating profit | -6 | -1 | 40 | 65 | 14 |
| Net profit | -6 | -6 | -13 | 24 | 3 |
| EPS (₹) | -0.95 | -1.13 | -2.49 | 4.69 | 0.54 |
Concall summary (2026-08-24)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Accordingly, the FY25 comparative and FY26 results have been restated to reflect the combined operations of Orchid Pharma and Dhanuka Laboratories.
- Combined employee and other operating expenses were broadly flat at INR353 crores in FY26 compared with approximately INR353 crores in FY25.
Growth & demand
- In a number of important products and markets, both volumes and pricing were affected, with declines of 15% to 20% depending on the product.
- Revenue from operations increased to INR304 crores in Q1 '27 from INR263 crores in corresponding quarter last year, representing growth of approximately 15%.
Margins & costs
- Consequently, combined gross margin moderated by approximately 4% to 32% in financial year '26 compared to approximately 36% in financial year '25.
- Combined gross margin improved by approximately 3% points to 33% in Q1 '27 compared with approxima tely 30% in Q1 of '26.
Capex & expansion
- We target commissioning by December of '26, followed by validation and initial batches during January to March '27 period.
- Finally, on the 7-ACA project, our objective remains unchanged, commissioning and the first commercial batch by March of '27.
Risks & challenges
- These statements are not guarantee of future performance and involve risks and uncertainties that are difficult to predict.
- It was among the most challenging environments our cephalosporin franchise has faced in the last 15 to 20 years.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.